Grail, a cancer diagnostics company, has announced plans to lay off approximately 350 employees, representing about 25% of its workforce, as part of a restructuring initiative aimed at focusing on its multi-cancer early detection (MCED) product, Galleri. The layoffs, alongside the elimination of 50 open positions, follow a portfolio review and are expected to save the company around $27 million in 2024, extending its cash runway to 2028. The restructuring will involve scaling back investments in non-core product programs and streamlining the commercial organization to prioritize high-potential provider territories. Grail reported a significant net loss of $1.6 billion for the second quarter, a stark increase from $193 million in the previous year, despite a revenue increase of 43% to $32 million. The company had previously been spun out from Illumina and was forced to separate again due to regulatory concerns regarding competition in the liquid biopsy market. Despite its challenges, Grail remains committed to advancing Galleri through the necessary FDA approval processes.